SCHIZO-MTCB1

Cannabinoid receptors CB1 in schizophrenia: role of brain mitochondrial activity and astroglial signalling

 Coordinatore INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) 

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Ms.
Nome: Sandra
Cognome: Barbary
Email: send email
Telefono: +33 5 57573635

 Nazionalità Coordinatore France [FR]
 Totale costo 194˙046 €
 EC contributo 194˙046 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2013-IEF
 Funding Scheme MC-IEF
 Anno di inizio 2015
 Periodo (anno-mese-giorno) 2015-02-01   -   2017-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Ms.
Nome: Sandra
Cognome: Barbary
Email: send email
Telefono: +33 5 57573635

FR (PARIS) coordinator 194˙046.60

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

brain    psychotic    schizophrenia    cb    receptor    symptoms    receptors    therapeutic    cannabinoid    mtcb    astrocytic    tools   

 Obiettivo del progetto (Objective)

'Schizophrenia is a severe psychiatric disorder characterized by a series of 'positive' and 'negative' symptoms, which eventually lead to strong sufferance, social isolation and occupational impairment. Via activation of type-1 cannabinoid receptors (CB1), cannabinoids are known to induce schizophrenic-like symptoms, which are major caveats in the possible therapeutic use of these compounds. On the other hand, mitochondria-dependent regulation of brain bioenergetics is emerging as a promising novel research path in the field of psychopathology of schizophrenia. Previous results suggest the implication of mitochondrial (mtCB1) and astrocytic-CB1 receptors in psychotic-like conditions. However the precise molecular and cellular links between ECS activity and schizophrenia are not known. The aim of this study is to test whether mithocondrial and/or astrocytic CB1 receptors represent a functional link between endocannabinoid signalling in the brain and psychotic-like behaviours. (1) Firstly, the project will be dedicated to the generation of specific genetic tools to clearly discriminate mtCB1 from other CB1 receptor locations in the cell. (2) Then, these specific tools and specific transgenic mice will be used to investigate the role of mtCB1 and astrocytic-CB1 receptor in 'psychosis-like' effects of cannabinoid drugs, and (3) to study the role of these receptors in a schizophrenia-like mouse model. This project will improve our understanding of the pathophysiology of psychotic-like disorders and might pave the way to novel therapeutic opportunities to improve the life of patients.'

Altri progetti dello stesso programma (FP7-PEOPLE)

NANOMEDICINE/IMAGING (2011)

Nanoparticle development for molecular imaging and drug delivery

Read More  

BIOTRANSOS (2011)

Design and evaluation of a bioadhesive film with easy peeling properties for transdermal drug delivery: application for osteoporosis treatment

Read More  

GRASSWALL (2014)

Maize Candy-leaf mutants: a tool for the study of grass-specific cell wall biology with potential applications in renewable energy production and cereal crop pathogen protection

Read More